Members Only Content

Subscribe to get full access

Free Preview

Shareholders are suffering more dilution because of the cell therapy and gene editing company's indecisiveness.

7investing's logo next to the Cellectis logo.

related news & insights

  • 7investing logo next to the Upstart logo.
    June 12, 2025||0 min||||

    Upstart Deep Dive: June 2025

    Upstart Recommendation Report Upstart Presentation Slides

  • May 30, 2025||0.8 min||||

    7investing Exclusive: A Deep Dive Into Lemonade

    Lemonade (NYSE: LMND) is a new player who's really adding zest to the insurance industry. Its AI-powered underwriting enables it to [...]

  • May 16, 2025||46.1 min||||

    What’s Next for Digital Advertising? 7investing Interviews PubMatic CEO Rajeev Goel

    PubMatic just reported first quarter 2025 results. Aside from the headwinds of a DSP partner changing its bidding process, the [...]